Leading UK Pharmacies trust Deltera
Deliver the latest plant-based nicotine substitute (Cytisinicline). This PGD manages the 25-day treatment course, with Deltera’s digital logic guiding the pharmacist through the rapid titration schedule for maximum success.
A Fully Digital Clinical Platform
Integrated Bookings and Payments
Secure & Connected Patient Records
Ditch the paperwork with secure digital records. Deltera automatically shares treatment summaries with the patient’s and sends the required notification to their GP instantly.
Training and Eligibility Requirements
To ensure clinical safety and regulatory compliance, all practitioners using this PGD must meet the following professional standards:
- Professional Registration: Must be a registered healthcare professional (e.g., Pharmacist) with a valid GPhC or PSNI registration and personal professional indemnity insurance.
- Clinical Competency: Practitioners must be self-certified as competent in the specific clinical area covered by this PGD and stay up to date with relevant national guidelines (e.g., The Green Book or NICE clinical summaries).
- Mandatory Training: Current certification in Basic Life Support (BLS) and the management of anaphylaxis is required for all injectable services.
- PGD Authorisation: The practitioner must have read and signed the PGD document within the Deltera Clinical Dashboard, with the authorisation counter-signed by the designated organisational lead or Superintendent.
- Premises Standards: Services must be conducted in a private consultation room that meets national standards for patient confidentiality and clinical safety.
Speak to the clinicians behind the platform
We understand the complexities of PGDs and clinical governance in the UK. Schedule a meeting with our team to see how we can help you navigate the changing landscape of community pharmacy.
Access related PGDs
FAQs
Generally, adults aged 18–65 motivated to quit. Deltera’s pre-screen checks for cardiovascular history and kidney function to ensure the patient meets the 2026 safety criteria.
The course is 25 days. Deltera’s patient portal provides a digital "quit calendar" to help the patient stay on track with their tapering dose throughout the month.
Typically, Cytisine is used as monotherapy. Deltera’s clinical logic flags if a patient is currently using other tobacco dependencies to prevent duplicate therapy.
Yes. Deltera generates an automated notification for the GP, ensuring the patient’s records reflect their quit attempt and the medication supplied.
Still have questions?
Our team are here to support you.
Discover Deltera Practice Management
Deltera Practice Management digitalises your private pharmacy services, providing the complete pharmacy software package to offer a full range of Patient Group Directions (PGDs). Gain the oversight and efficiency you need to thrive.
